SUINING, China, Oct. 22 /Xinhua-PRNewswire/ -- China Health Resource, Inc. (OTC Bulletin Board: CHRI) announced today that it has signed a cooperation contract with Guangzhou Qingping Trade Center (“Qingping”), one of the four biggest herbal medicine and healthcare products markets in China. CHRI will, according to the contract, establish a South China Sales and Logistics Center for Suining Chuan Dahurian Angelica Root (DAR) and related products in Qingping, meanwhile, Qingping will greatly boost the sales of Chuan DAR and related products in the area with its great influence in Southeast Asia’s herbal medicine markets.
The CHRI South China Sales and Logistics Center is located at the Phase II transaction section of Guangzhou Qingping Trade Center with a 300 square meter first-class office, a 220 square meter exhibition center, and an 1800 square meter international-standard warehousing center. It’s a signal of the beginning of the market expansion in South China and Southeast Asia. The South China Sales and Logistics Center is predicted to generate revenue of $2.5 million annually.
Guangzhou Qingping Trade Center has a history of 20 years. It is the biggest trading market and distribution center, as well as the biggest import-export trading port of medicine and healthy food materials. According to the official data, the gross trading revenue of the market in 2006 was $0.4 billion. The daily customer flow is 100,000 people. It is expected that trading revenues will hit $0.66 billion in 2008.
About the Company
China Health Resource, Inc. (CHRI) was incorporated on April 24, 2001. It is one of China’s leading industrialized agricultural corporations. CHRI focuses on the production and further processing of Dahurian Angelica Root (DAR), a herb that is widely used and considered to be an important ingredient in Chinese traditional medicines. CHRI’s business plan includes distributing DAR and the processed products to exploit a large market in the areas of treatment of pain, swelling and pustule. Good Agricultural Practice (GAP) is a national compulsory criterion for food and drug industries. The goal of GAP is to help agricultural product companies deal with the usual micro-organism harm so as to strengthen agricultural product safety. CHRI has accomplished the GAP certification of Chuan DAR, making the DAR products and related production technology of the Company become the industry criteria.
Statements regarding financial matters in this press release other than historical facts are ‘forward-looking statements’ within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such proclamations about future expectations, including future revenues and earnings and all other forward-looking statements be subject to the safe harbors created thereby. CHRI depends on outside resources to maintain its continuation. Since these statements involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results.
For more information, please contact:
China Health Resource, Inc.
Tel: +86-825-2391788
343 Suining Zhong Road, Suining, Sichuan, P.R. China
Web: http://www.chinahealthresources.com
